Market Outlook by Division and Business Unit

Key growth drivers

Investor Day 2023

Kevin Lobo
Chair and CEO

"We remain confident in the outlook of our business and expect to continue to deliver sales growth at the high end of MedTech, driven by our robust pipeline of innovation, developing solutions to raise the standard of patient care."

"Our top-line strength starts with innovation across our diversified portfolio. Bringing meaningful value to the OR through innovation remains a key pillar for growth at the high end of MedTech."

Glenn Boehnlein
VP, CFO

Forward-looking statements

This presentation contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions, or the anticipation thereof, that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign currency exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect United States Food and Drug Administration approval of new products; inflationary pressures; increased interest rates; supply chain disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to recall-related matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; changes in tax laws and regulations; the impact of federal legislation to reform the United States healthcare system; costs to comply with medical device regulations; changes in financial markets; changes in our credit ratings; changes in the competitive environment; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes; our ability to realize anticipated cost savings; potential negative impacts resulting from environmental, social and governance (ESG) and sustainability related matters; the impact on our operations and financial results of any public health emergency and any related policies and actions by governments or other third parties; and breaches or failures of our or our vendors' information technology systems or products, including by cyber-attack, data leakage, unauthorized access or theft. Additional information concerning these and other factors is contained in our filings with the United States Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Table of **contents**

Medsurg and Neurotechnology

"It's a privilege to be part of healthcare. Our depth and specialization set us apart, and all for one crucial purpose: to improve people's lives."

Andy Pierce
Group President, Medsurg & Neurotechnology

Orthopaedics and Spine

"We remain focused on specialization and addressing unmet needs. Creating solutions for the customer and improving outcomes is core to our mission and values."

Spencer Stiles
Group President, Orthopaedics & Spine

Medsurg and Neurotechnology

Segment overview

Est. market size*	Est. market CAGR through '26
Endoscopy: $16B	Endoscopy: MSD
Medical: $13B	Medical: HSD
Instruments: $5B	Instruments: HSD
NeuroCranial: $5B	NeuroCranial: MSD
Neurovascular: $4B	Neurovascular: HSD

Orthopaedics and Spine

Segment overview

Est. market size*	Est. market CAGR through '26
Joint Replacement: $15B	Joint Replacement: MSD
Spine: $13B	Spine: LSD
Trauma and Extremities: $11B	Trauma and Extremities: MSD

*Based on company research

Innovation spotlight

1788 Camera

The 1788 Platform features several enhancements for a broader range of clinical applications and specialties, including urology, neurology, and ear, nose and throat. In addition, 1788 can be used to visualize ICG and Cytalux.

Launched 3Q23

Xpedition

Xpedition is Stryker's first powered stair chair, designed with an integrated workflow for first responders, maintaining the same storage footprint as Stryker's Stair-PRO and enhanced user interface for ease of use. Xpedition allows caregivers to safely and ergonomically move patients over a variety of terrains.

Launched 1Q23

System 9

System 9 now comes with repositioned battery indicators, providing better visibility to surgeons and the surgical team, indicating that the power tool is ready to perform. The twist-lock handpiece to battery interface drives assembly efficiency through tactile and visual feedback. Additionally, the handpieces have an ergonomic design that reduces the number of pressure points and accommodates inverted cutting. The new wireless charger allows users to charge the tool whenever and wherever they want, even through blue wrap.

Launched 4Q22

Cranial Guidance

Cranial guidance delivers groundbreaking surgical planning and guidance capabilities via active/passive hybrid optical tracking – plus optional, scalable modules for navigated brain biopsy and EM Catheter Placement, receiving strong positive feedback during validation labs.

Launched 3Q23

Insignia Hip Stem

The Insignia hip stem leverages more than 1300 CT scans, utilizing a 3D modeling and analytics system, and is engineered to optimize fit and function. The collared, metaphyseal-filling hip stem is designed specifically for muscle-sparing approaches.

Launched 3Q22

Mako Total Knee 2.0

Mako Total Knee 2.0 drives ease of use through its intuitive design, a customizable step-by-step workflow and innovative features – including a digital tensioner that allows surgeons to assess the knee's stability intraoperatively during a total knee arthroplasty (TKA) without any additional instrumentation.

Launched 3Q23

MedSurg and Neurotechnology

Andy Pierce
Group President, MedSurg and Neurotechnology

Endoscopy

Segment overview

Est. market size*	Est. market CAGR through '26
Endoscopy TAM: $16B	**Endoscopy CAGR ('24 – '26): MSD**
Surgical Visualization**: $8B	Surgical Visualization: MSD
Sports Medicine: $5B	Sports Medicine: MSD
Communications: $3B	Communications: MSD

1788 Camera

L12 Lightsource

InSpace Balloon

iSuite

*Based on company research **Surgical Visualization includes Sustainability Solutions

Key drivers

Launch of the **1788 Camera**.
Winning build contracts in **Communications**.
Strength in the ASCs across the **Sports Med** portfolio.

Surgical visualization

Designed for ease of use and OR safety allowing surgeons and OR staff to focus on the mechanical aspects of the procedure.

Key products: 1788, SPY-PHI, L12 Lightsource, Surgical Displays

Communication

A customized integrated OR ecosystem, that is designed to support patient and caregiver safety, increase operational efficiency, and connect surgical devices to improve workflow, resulting in enhanced patient and staff satisfaction.

Key products: iSuite, Surgical Booms, Surgical Lights, Surgical Tables, Integration and Connectivity Solutions

Sports Medicine

An integrated sports medicine product portfolio inclusive of the latest technology for arthroscopic and open shoulder, hip, knee and small joint procedures.

Key Products: InSpace, Pivot Guardian Total Hip System, HipMap, HipCheck, AIR+, AlphaVent

Medical

Segment overview

Est. market size*	Est. market CAGR through ‘26
Medical TAM: $13B	**Medical CAGR (‘24- ‘26): HSD**
Emergency Care: $3B	Emergency Care: HSD
Acute Care: $8B	Acute Care: MSD
Sage: $2B	Sage: HSD


Vocera Smartbadge


LIFEPAK 15 v4+


ProCuity ZM Model


Power-PRO 2


Sage Oral Hygiene Portfolio

*Based on company research

Key drivers

Launch of **Xpedition powered stair chair**.
Multi-year momentum of **ProCuity**.
Cross-sell opportunities and platform acceleration of **Vocera**.
Consistent, strong growth across **Sage portfolio**.

Emergency Care

Providing life saving tools for life saving teams in the back of the ambulance, in the hospital, and in the community and workplaces.

Key products: Xpedition, LUCAS, LIFEPAK, LIFENET, CR2, Power-PRO 2

Acute Care

Deliver advanced technologies and total solutions to enhance the clinical workflow and experience while enabling safer care and better outcomes across the continuum of care.

Key products: ProCuity, Vocera, Prime, Unity

Sage

Simple interventions driving extraordinary outcomes.

Key products: Oral hygiene, Urine management, Pre-op prep stryker

Instruments

Segment overview

Est. market size*	Est. market CAGR through ‘26
Instruments TAM: $5B	**Instruments CAGR (‘24- ‘26): HSD**
Orthopaedic Instruments: $3B	Orthopaedic Instruments: MSD
Surgical Technologies: $2B	Surgical Technologies: DD



System 9

CD NXT

T7 Personal Protection

Neptune S

SafeAir

*Based on company research

Key drivers

Continued momentum of **System 9 and Neptune S**.
Progression of US **smoke legislation**.
Future innovation with **System 9 CD NXT**.
Mix benefit from product innovation.

Orthopaedic Instruments

Delivering innovative products and services for the Orthopaedic ecosystem.

Key products: System 9, CD NXT, TPX, T7

Surgical Technologies

Provide a safer, simpler experience for caregivers and their patients through our journey to zero harm.

Key products: Neptune S, SafeAir, SurgiCount, Triton

NeuroCranial

Segment overview

Est. market size*	Est. market CAGR through ‘26
NeuroCranial TAM: $5B	**NeuroCranial CAGR (‘24- ‘26): MSD**
Craniomaxillofacial: $2B	Craniomaxillofacial: MSD
NeuroSurgical: $2B	NeuroSurgical: HSD
ENT: $1B	ENT: MSD

Sonopet IQ

Cranial ID

Universal Neuro III

BoneMill+

*Based on company research

Key drivers

Market development driven by **BoneMill+**.
Key customer conversion across **CMF segments**.
Continued **price and mix** momentum.

Craniomaxillofacial

Overcoming obstacles begins by understanding them, through our rich history of experience in the field of craniomaxillofacial surgery.

Key products: DuraMatrix, DirectInject, MEDPOR, Universal Mesh

Neurosurgical

Innovative ideas, performance-enhancing products and deep, collaborative relationships in Neuro, Spine, and ENT.

Key products: BoneMill+, Maestro Air, Quantum Headlight

ENT

Over 20 years of research and development of surgical ENT products reflects the heritage that has made us a world leader in medical technology.

Key products: Audion, FocESS, ClariFix, Cyclone irrigation, ENT Navigation

Neurovascular

Segment overview

Est. market size*	Est. market CAGR through ‘26
Neurovascular TAM: $4B	**Neurovascular CAGR (‘24 – ’26): HSD**

Contour Neurovascular System

Target Tetra Detachable Coil

AXS Vecta Portfolio

Synchro Guidewire

*Based on company research

Key drivers

Acquisition of **Cerus Endovascular**.
Launch of the **Target Tetra coil**.
Strong **international growth** opportunity.
Market leader in **complete stroke care**.
Growth in **NV adjacencies**.

Hemorrhagic

Advancing the practice of less invasive therapies through highly effective hemorrhagic stroke and access products.

Key products: Contour Neurovascular System, Target Detachable Coil, Surpass Evolve Flow Diverter, Neuroform Atlas, Synchro Guidewire

Ischemic

Advancing the practice of less invasive therapies through innovative ischemic stroke products and services.

Key products: Trevo NXT ProVue Retriever, Trevo Trak 21 Microcatheter, AXS Vecta Catheters

Orthopaedics and Spine

Spencer Stiles
Group President, Orthopaedics and Spine

Joint Replacement

Segment overview

Est. market size*	Est. market CAGR through ‘26
Joint Replacement TAM: $15B	**Joint Replacement CAGR (‘24- ‘26): MSD**
Hips: $7B	Hips: MSD
Knees: $8B	Knees: MSD

Triathlon Cementless

Comprehensive Joint Portfolio

Insignia Hip Stem

*Based on company research

Key drivers

Accelerated **utilization in robotic procedures**.
Continued **global expansion**.
Strong growth in the **ASC space**.
Market leading **cementless offering** in knees.

Hips

Market-leading implants for total hip arthroplasty, designed to offer a wide variety of implants, instrumentation to match a surgeon's needs including for muscle-sparing approaches.

Key products: Insignia, Restoration Modular, Trident II, Accolade II

Knees

Implants for partial and total knee arthroplasty for primary and revision procedures. Our implants feature our flagship cemented and cementless TKA solution, the Triathlon Knee System.

Key products: Triathlon Total Knee System, Triathlon TS, Triathlon Hinge, Restoris MCK

Mako

Segment overview

Global statistics	Robotic mix US
+1 Million Mako procedures with Mako Total Knee, Mako Total Hip and Mako Partial Knee	Hips: >29% robotic hips implanted
40 Countries	Knees: >57% robotic knees implanted
17 Years	
Over 330 published, peer reviewed studies	
1,500+ patents	
105 Million actionable data points	

Mako

Mako UI

Mako Saw
End Effector

Hip and Knee

Mako SmartRobotics™ has demonstrated better patient outcomes for Partial Knee, Total Hip and Total Knee patients.[1,2,3] Mako enables increased precision and accuracy to plan compared to manual surgery,[4,5,6] supporting a more predictable surgical experience.

Key utilization drivers: Mako 3D CT-based planning, AccuStop™ haptic guidance bone preparation, trusted implants

Upcoming new market entry* - Shoulder

The Mako Shoulder application will be compatible with Stryker's Perform implants. The initial release will incorporate Blueprint as the pre-operative planning solution. The Mako Shoulder application, coupled with Blueprint, is being designed to deliver an accurate and reproducible execution of the plan with the ability to adjust the plan intraoperatively.

Key utilization drivers: Implants, Bone cutting and milling capabilities and ease of use.

Upcoming new market entry* - Spine

The Mako Spine application will integrate with the Q Guidance System, our fourth-generation surgical guidance platform, and Spine Guidance Software which aims to deliver more surgical planning and navigation capability than ever before.

Key utilization drivers: trajectory guidance, ease of use, consistent user experience

*currently under development and has not yet received clearance for sale. Final details and descriptions may change.

Spine

Segment overview

Est. market size*	Est. market CAGR through ‘26
Spine TAM: $13B	**Spine CAGR (‘24- ‘26): LSD**
Core Spine**: $11B	Core Spine: LSD
Enabling Technologies: $2B	Enabling Technologies: DD

Q Guidance System with Spine Guidance Software and Cranial Guidance Software



Airo TruCT

Monterey AL



Everest

AutoPlex Mixer and Delivery System

Key drivers

Acceleration of **enabling technology growth**.
Market growth driven by **robotic procedures**.*
Share opportunity from **market consolidation**.

Spine

A broad portfolio of spine procedural solutions enhanced by guidance and imaging technologies to treat complex pediatric and adult pathologies as well as degenerative thoracolumbar and cervical pathologies.

Core Spine

Our core technologies include biologic solutions, spinal implants, and surgical instruments for use in spine procedures.

Key products: Monterey AL (newest implant in the Tritanium portfolio), Everest, Serrato, Yukon, Vitoss, Ozark

Enabling Technologies

Our enabling technologies include products for both spine and cranial procedures.

Key products: Q Guidance System with Spine Guidance and Cranial Guidance Software, Airo TruCT

*Stryker Spine does not have robotic-assisted surgery products on the market

*Based on company research

**Core Spine incudes IVS

Trauma and Extremities

Segment overview

Est. market size*	Est. market CAGR through '26
T&E TAM: $11B	**T&E CAGR ('24 – '26): MSD**
Core Trauma: $5B	Core Trauma: LSD
Upper Extremities: $2B	Upper Extremities: HSD
Foot & Ankle: $4B	Foot & Ankle: MSD

Gamma4 Hip Fracture Nail

Tornier Perform Humeral Stem

Blueprint (Shoulder)

Infinity Total Ankle Replacement

Augment Regenerative Solution

*Based on company research

Key drivers

Momentum of UE and F&A in the U.S.
Strong growth in F&A driven by **total ankle replacement**.
Steady **cadence of innovation** continues to drive above market growth.
Salesforce specialization.

Trauma

Focused on the needs of orthopaedic trauma surgeons and dedicated to developing market-leading implants for the treatment of long and small bone fractures.

Key products: Gamma4, T2 Alpha, Hoffmann 3, VariAx

Foot & Ankle

Dedicated to helping foot and ankle surgeons treat their patients more efficiently while enhancing patient care and the overall healthcare experience.

Key products: Infinity, PROstep MIS, Lapifuse, Augment

Upper Extremities

Continued innovation of shoulder replacement implants working in conjunction with digital and enabling technologies to make better outcomes easier.

Key products: Perform Humeral Platform, Blueprint, Mixed Reality and Shoulder ID stryker

References

1. Kayani B, Konan S, Tahmassebi J, Pietrzak JRT, Haddad FS. Robotic-arm assisted total knee arthroplasty is associated with improved early functional recovery and reduced time to hospital discharge compared with conventional jig-based total knee arthroplasty: a prospective cohort study. Bone Joint J. 2018;100-B(7):930-937. doi:10.1302/0301-620X.100B7.BJJ-2017-1449.R1
2. Kayani B, Konan S, Tahmassebi J, Rowan FE, Haddad FS. An assessment of early functional rehabilitation and hospital discharge in conventional versus robotic-arm assisted unicompartmental knee arthroplasty: a prospective cohort study. Bone Joint J. 2019;101-B(1):24-33. doi:10.1302/0301-620X.101B1.BJJ-2018-0564.R2]
3. Shibanuma N, Ishida K, Matsumoto T, et al. Early postoperative clinical recovery of robotic arm-assisted vs. image-based navigated Total hip Arthroplasty. BMC Musculoskelet Disord. 2021;22(1):314. Published 2021 Mar 29. doi:10.1186/s12891-021-04162-3
4. Deckey DG, Rosenow CS, Verhey JT, et al. Robotic-assisted total knee arthroplasty improves accuracy and precision compared to conventional techniques. Bone Joint J. 2021;103-B(6 Supple A):74-80. doi:10.1302/0301-620X.103B6.BJJ-2020-2003.R1
5. Bell SW, Anthony I, Jones B, MacLean A, Rowe P, Blyth M. Improved Accuracy of Component Positioning with Robotic-Assisted Unicompartmental Knee Arthroplasty: Data from a Prospective, Randomized Controlled Study. J Bone Joint Surg Am. 2016;98(8):627-635. doi:10.2106/JBJS.15.00664
6. Sicat CS, Buchalter DB, Luthringer TA, Schwarzkopf R, Vigdorchik JM. Intraoperative Technology Use Improves Accuracy of Functional Safe Zone Targeting in Total Hip Arthroplasty. J Arthroplasty. 2022;37(7S):S540-S545. doi:10.1016/j.arth.2022.02.038

Footnotes

1. Acronym glossary: (LSD) Low-Single Digit; (MSD) Mid-Single Digit; (HSD) High-Single Digit; (DD) Double Digit; (TAM) Total Addressable Market; (CAGR) Compound Annual Growth Rate